ibrutinib
janssen,abbvie
['mantle,(-dismantle)', 'ibru', 'lymphoma']
the largest trial to date in #mantlecelllymphoma #mcl shows that adding the bruton's tyrosine kinase (#btk) inhibitor #ibrutinib (imbruvica) to standard of care treatment improves progression-free survival (#pfs) by 50%.
#asco2022 
Pharma, Biopharma, Biotech, Clinical Trial, Stock, Fund, Index